Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $10.35M
• Dividend Yield: N/A
• Average Volume (3M): 302.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 71
• Sector: Healthcare
• Sector Strength: 78
• Industry: Medical Diagnostics & Screening
• EPS (TTM): -65.57
• Shares Outstanding: 2,221,597
• 10 Day Avg. Volume: 165,832
• 30 Day Avg. Volume: 302,649
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 45.73
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.00
• Price Target Upside: 200.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Mainz Biomed B.V.'s overall stock score is primarily affected by its weak financial performance, characterized by consistent losses, high leverage, and negative cash flow. The technical analysis indicates mixed signals with a slight bearish trend. The lack of profitability is reflected in the negative P/E ratio, and the absence of a dividend yield further affects valuation. These factors collectively result in a below-average stock score.

Positive Factors

Partnerships

The company announced a collaborative agreement with Thermo Fisher Scientific to jointly develop and potentially commercialize Mainz’s next generation mRNA-based screening tests for global markets.

Product Innovation

Mainz Biomed's Next-Generation Test has transformative potential in the $4B CRC screening segment in the US by enabling accurate detection of precancerous AAs with a decentralized commercial strategy to accelerate adoption and reduce commercial expenses.

Negative Factors

Financial Performance

Net loss totaled $11.0M in the first half of the year, with revenue being only $0.5M, indicating financial challenges.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

How the Company Makes Money

Mainz Biomed generates revenue through the sale and distribution of its diagnostic products, particularly ColoAlert. The company targets healthcare providers, clinics, and laboratories, partnering with medical institutions to offer its testing solutions to patients. Revenue is primarily derived from the sales of test kits and related services, including analysis and reporting of test results. Mainz Biomed may also engage in strategic collaborations or partnerships with other biotech firms or research institutions to expand its product offerings and market reach, contributing to its earnings.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. operates in the Medical Diagnostics & Screening industry and faces considerable financial difficulties. While there is some revenue growth and improvement in gross profit margin, the company is struggling with substantial losses and cash flow issues. The high leverage and low equity base pose additional risks, potentially impacting its financial health and operational sustainability.

Income Statement

Mainz Biomed B.V. has shown some revenue growth over time; however, the company remains unprofitable with negative EBIT and net income consistently. The gross profit margin improved from previous years, but the net profit margin is substantially negative, indicating significant operational challenges.

Balance Sheet

The company's balance sheet shows an improvement in stockholders' equity over the years, yet it remains highly leveraged with a rising debt-to-equity ratio. The equity ratio is very low, reflecting potential risks in financial stability.

Cash Flow

The operating cash flow is persistently negative, and free cash flow has worsened over the years. The company faces significant challenges in generating cash from operations, which indicates potential liquidity issues.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
895.48K	529.88K	577.35K	493.56K	281.39K
	Gross Profit
509.66K	182.15K	177.62K	123.08K	-61.27K
	EBIT
-26.64M	-26.17M	-9.38M	-325.81K	-921.91K
	EBITDA
-25.01M	-25.72M	-11.28M	-257.64K	-702.08K
	Net Income Common Stockholders
-26.30M	-26.45M	-12.07M	-886.18K	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.07M	17.14M	8.73M	122.57K	203.59K
	Total Assets
15.41M	20.24M	10.04M	673.27K	715.96K
	Total Debt
7.42M	3.23M	2.58M	2.98M	2.41M
	Net Debt
349.86K	-13.91M	-6.15M	2.86M	2.21M
	Total Liabilities
12.16M	6.14M	3.68M	3.41M	2.67M
	Stockholders Equity
3.25M	14.10M	6.36M	-2.74M	-1.95M
Cash Flow		Free Cash Flow
-23.84M	-15.43M	-3.24M	-478.42K	-416.50K
	Operating Cash Flow
-21.94M	-14.77M	-3.22M	-468.74K	-416.50K
	Investing Cash Flow
-1.90M	-658.48K	1.20M	-9.69K	0.00
	Financing Cash Flow
14.23M	23.94M	10.61M	396.68K	424.00K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 4.66 is below the 20-day moving average (MA) of 5.57, below the 50-day MA of 5.44, and below the 200-day MA of 11.67, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 26.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMO	70 Outperform	$198.74B	32.15	13.15%	0.30%	0.05%	6.87%
QGEN	66 Neutral	$8.54B	105.65	2.27%	―	0.66%	―
EXAS	53 Neutral	$8.52B	―	-37.09%	―	10.37%	-389.98%
GH	53 Neutral	$5.26B	―	-4584.47%	―	31.04%	16.91%
ILMN	49 Neutral	$13.39B	―	-30.11%	―	-2.93%	-4.69%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
MYNZ	42 Neutral	$10.35M	―	-809.29%	―	―	―